A new study has found that a wholesale synthetic and non-intoxicating version of CBD has effectively treated seizures in rats. The CBD alternative, known as 8,9-Dihydrocannabidiol (H2CBD) is a synthetic molecule with a similar structure to CBD. The single largest difference being, unlike CBD, there is no way to convert H2CBD to the intoxicating THC.
The new research, published just this week, May 28, 2019, was conducted by the University of California, Davis. It concluded that the alternative cannabinoid was not only easier to purify than a plant extract, but that it eliminated the use of agricultural land for hemp cultivation. It could also help avoid legal complications in the UK associated with cannabis-related products.
The California University carried out their work in collaboration with researchers at the University of Reading, UK, published in the journal of Scientific Reports. Head researcher Mark Mascal, Professor in the UC Davis Department of Chemistry has said, “It's a much safer drug than CBD [H2CBD], with no abuse potential and doesn't require the cultivation of hemp”.
The trial period saw researchers test synthetic H2CBD against herbal CBD in rats with induced seizures. Both H2CBD and CBD were found to be equally effective in the reduction of both the frequency and severity of seizures. These findings are substantial when we consider the grey area that continues to exist around CBD’s legal status in both the UK and US.
Mascal will continue to work with colleagues at the UC Davis School of Medicine to carry out more animal studies, in the hope of moving into a clinical trial phase soon. UC Davis has also officially applied for a provisional patent on the anti-seizure use of H2CBD and its analogues. Professor Mascal has founded the company, Syncanica, to continue this development.
Recently, products containing CBD have been vastly growing in popularity and it’s all down to the compound’s many possible health benefits, as well as the fact that CBD does not cause a high.
It is currently being investigated as a pharmaceutical compound for many conditions including, epilepsy, glaucoma, anxiety, and arthritis. And, just last year the FDA officially approved its first cannabis-based medicine, Epidiolex, for the treatment of severe forms of epilepsy.
CBD, however, does still pose legal problems in the UK and in some states under federal law. Mascal’s study has also claimed that ‘it is possible to chemically convert CBD to tetrahydrocannabinol (THC), the intoxicating compound in marijuana’. If so, could we see soon see H2CBD stealing the spotlight from CBD? Only time will tell.
The line is old and never made sense in the first place, but politician after politician like to extol the fear that if they legalize cannabis, everyone will become a pothead. As it turns out, study after study say the opposite, that legalizations don’t increase cannabis use, particularly in younger populations. Take a look. Yet […]
The post Another Study Says Legalizations Don’t Increase Cannabis Use appeared first on Cannadelics.
All eyes are on Switzerland as the country makes big moves to start its own cannabis industry. The country announced plans for a recreational measure last year, and now Switzerland is introducing a wide-reaching medical program that goes far beyond its previous limits. Switzerland is on a rampage, both widening its medical cannabis program, and […]
The post Switzerland Implements Wide-Reaching Medical Cannabis Program appeared first on Cannadelics.
The psychedelics industry is gearing up for a massive debut, and opinions on the compounds are changing for the better. How popular are psychedelics in America right now? New survey results show that these compounds are not unknown to the American public, and that close to 30% of respondents, have already tried them. With the […]
The post How Popular Are Psychedelics In America? Survey Says ~30% Have Tried appeared first on Cannadelics.
Summer Savings Sale